[
    "{\"step_by_step_thinking\": \"Based on the information provided in the documents, Selinexor has been shown to be effective for multiple myeloma. Document [1] states that Selinexor in combination with dexamethasone has emerged as a viable option for heavily pretreated triple-class relapsed and refractory multiple myeloma (RRMM). Document [3] mentions that Selinexor in combination with dexamethasone received accelerated FDA approval for heavily pretreated patients with relapsed/refractory MM based on the promising results of the Phase II STORM trial. Document [8] also highlights that Selinexor has demonstrated activity in a heavily refractory patient population. Therefore, the answer is A. yes.\", \"answer_choice\": \"A\"}"
]